B01AC16 • eptifibatide • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin
Eptifibatide is an antiplatelet medication used to prevent blood clot formation in patients with acute coronary syndromes or those undergoing coronary angioplasty procedures. It works by inhibiting platelet aggregation, thus reducing the risk of myocardial infarction or other cardiovascular complications.
Eptifibatide is administered intravenously under strict medical supervision, usually in a hospital setting, before, during, or after cardiac procedures. The dose is adjusted according to the patient's weight and the doctor's instructions.
Side effects may include bleeding, decreased platelet count, allergic reactions, or, rarely, hypotension. Careful monitoring of blood parameters is essential during treatment.
Eptifibatide is an effective option for reducing the risk of thrombotic complications in patients with heart conditions, but its use requires specialized medical supervision.
Substance: eptifibatide
Date of last drug list: 01-06-2025
Commercial code: W70258001
Concentration: 0.75mg / ml
Pharmaceutical form: infusion solution
Quantity: 1
Product type: generic
Price: 384.66 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ROMPHARM COMPANY S.R.L. - ROMANIA
Holder: ROMPHARM COMPANY S.R.L. - ROMANIA
Number: 15436/2024/01
Shelf life: 1 year